BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) today announced that its Chief Operating
Officer, Andrew Robbins, will speak
at the Goldman Sachs 40th Annual Global Healthcare Conference in
Rancho Palos Verdes, California.
The public is welcome to participate in the conference through a
webcast on the Array BioPharma website.
|
Event:
|
Goldman Sachs 40th
Annual Global Healthcare Conference
|
|
Presenter:
|
Andrew Robbins, Chief
Operating Officer, Array BioPharma
|
|
Date:
|
June 11,
2019
|
|
Time:
|
3:20 p.m. Pacific
Time / 6:20 p.m. Eastern Time
|
|
Webcast:
|
https://cc.talkpoint.com/gold006/061119a_as/?entity=45_2CLGG3P
|
About Array BioPharma
Array BioPharma Inc. is a fully
integrated biopharmaceutical company focused on the discovery,
development and commercialization of transformative and
well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden diseases. Array markets
BRAFTOVI® (encorafenib) capsules in combination with
MEKTOVI® (binimetinib) tablets for the treatment of
patients with unresectable or metastatic melanoma with a
BRAFV600E or BRAFV600K mutation
in the United States and with
partners in other major worldwide markets. Array's lead clinical
programs, encorafenib and binimetinib, are being investigated in
over 30 clinical trials across a number of solid tumor indications,
including a Phase 3 trial in BRAF-mutant metastatic
colorectal cancer. Array's pipeline includes several additional
programs being advanced by Array or current license-holders,
including the following programs currently in registration trials:
selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with
Eli Lilly), ipatasertib (partnered with Genentech), tucatinib
(partnered with Seattle Genetics) and ARRY-797.
Vitrakvi® (larotrectinib, partnered with Bayer AG) is
approved in the United States and
Ganovo® (danoprevir, partnered with Roche) is approved
in China. For more information on
Array, please visit www.arraybiopharma.com or follow
@arraybiopharma on Twitter and LinkedIn.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-300861784.html
SOURCE Array BioPharma Inc.